Moreover, the activity of PRMT5 inhibitors in oncogene-driven NSCLC is not well established.<h4>Methods</h4>We assessed MTAP expression by immunohistochemistry (IHC) in 243 NSCLCs (n=132 early stage, n=111 metastatic), including 33 specimens with paired lymph nodes. Here, PRMT5 is linked to non-small cell lung carcinoma.